TGF-beta-induced non-Smad signaling events and cancer cell behavior

TGF-β诱导的非Smad信号传导事件和癌细胞行为

基本信息

  • 批准号:
    8020129
  • 负责人:
  • 金额:
    $ 31.1万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2009
  • 资助国家:
    美国
  • 起止时间:
    2009-01-01 至 2013-12-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Transforming growth factor-¿ (TGF-¿) plays a critical role in cancer initiation and progression. Carcinoma cells often have shown enhanced TGF-¿ production and activation, resulting in autocrine effects on cell physiology and behavior. Among these, a lot of attention has focused on TGF-¿'s ability to induce an epithelial to mesenchymal transition (EMT) that results in de-adhesion, increased motility and invasion. The roles of TGF-¿ in cancer cell behavior, tumor microenvironment and cancer progression are subject of extensive investigation, but the respective roles of the underlying TGF-¿-activated signaling pathways in cancer cell behavior are less understood. Most studies in this context address the roles of TGF-¿-activated Smads, which serve as transcription (co)factors to regulate gene expression. Recent studies, including some from this lab, have characterized non-Smad signaling pathways that are directly activated in response to TGF-¿. These may explain non-transcription responses to TGF-¿ such as migration, changes in cell shape and protein translation, yet may also affect the activities of the Smads. The functions of the non-Smad signaling events in the TGF-¿-directed effects on cancer cell behavior and cancer progression are essentially unknown. We recently reported that, in TGF-¿-induced epithelia EMT, TGF-¿ activates the PI3-kinase-Akt-TOR pathway, resulting in increased protein synthesis and cell size, and that this pathway mediates the increased motility and invasion of cells that undergo TGF-¿-induced EMT. We also reported that, in response to TGF-¿, ShcA is recruited to the type I TGF-¿ receptor T¿RI and phosphorylated on Ser and Tyr, in turn resulting in activation of Erk MAP kinase. Our observation that T¿RI is a dual specificity kinase explains ShcA phosphorylation on Ser and Tyr, whereas T¿RI phosphorylation on Tyr in response to TGF-¿ may provide the biochemical basis for activation of both the PI3K-Akt-TOR and the Shc-Erk MAPK pathways by TGF-¿. Finally, we discovered that phosphorylation of T¿RI in response to TGF-¿ induces T¿RI sumoylation. T¿RI sumoylation in turn regulates TGF-¿-signaling dependent invasion of cancer cells. We propose to further characterize the mechanisms of these signaling events at the molecular level and to use this knowledge to address their roles in cancer cell behavior and cancer progression. Aim 1 will focus on how TGF-¿ activates the PI3K-Akt-TOR pathway and on the role of this component of TGF-¿ signaling in cell invasion and cancer progression. Aim 2 will study the role of TGF-¿-activated ShcA-Erk MAP kinase signaling in EMT, invasion and cancer progression. Aim 3 proposes to better characterize the sumoylation of T¿RI and to understand its role in the TGF-¿ response and cancer progression. Our enthusiasm for this program is driven not only by its inherent scientific importance, but also by its translational potential. PUBLIC HEALTH RELEVANCE: The progression of cancer leading to death is in most cases not the result of the first tumor growing, but rather because that tumor starts invading other tissues and disseminating throughout the body to give rise to additional tumors, a process called metastasis. Cancer invasion and metastasis are driven by a protein called TGF-¿, which is made by the tumor cells themselves and instructs them to undergo the changes that lead to invasion and metastasis. Recently, novel signaling pathways were found that are activated by TGF-¿ and complement the previously studied one that received all attention. The proposed research aims at better understanding the molecular basis of these additional pathways and their roles in cancer cell behavior, cancer progression and metastasis. This knowledge is likely to provide new and more selective avenues than hitherto possible to block the invasive and metastatic behavior of cancers.
描述(由申请人提供):转化生长因子-<$(TGF-<$)在癌症发生和进展中起关键作用。 癌细胞通常表现出增强的TGF-β产生和活化,导致对细胞生理和行为的自分泌效应。 其中,大量的注意力集中在TGF-β诱导上皮细胞向间质细胞转化(EMT)的能力,导致去粘附,增加运动性和侵袭性。 TGF-β的作用在癌细胞行为中,肿瘤微环境和癌症进展是广泛研究的主题,但对潜在的TGF-β激活的信号通路在癌细胞行为中的各自作用了解较少。 这方面的大多数研究都涉及TGF-β激活的Smads的作用,Smads作为转录(辅助)因子调节基因表达。 最近的研究,包括本实验室的一些研究,已经表征了非Smad信号通路,这些信号通路直接响应TGF-β而被激活。 这些可以解释对TGF-β的非转录反应,如迁移,细胞形状和蛋白质翻译的变化,但也可能影响Smads的活性。 非Smad信号传导事件在TGF-β对癌细胞行为和癌症进展的作用中的功能基本上是未知的。 我们最近报道,在TGF-β诱导的上皮细胞EMT中,TGF-β激活PI 3-激酶-Akt-TOR通路,导致蛋白质合成增加和细胞大小增加,并且该通路介导经历TGF-β诱导的EMT的细胞的运动性和侵袭性增加。 我们还报道,在对TGF-β的反应中,ShcA被募集到I型TGF-β受体T-RI上,并在Ser和Tyr上磷酸化,进而导致Erk MAP激酶的激活。 我们观察到,RI是一种双特异性激酶,可解释ShcA在Ser和Tyr上的磷酸化,而T <$RI在Tyr上的磷酸化可为TGF-<$激活PI 3 K-Akt-TOR和Shc-Erk MAPK通路提供生化基础。 最后,我们发现T_R1的磷酸化对TGF-β的反应诱导T_R1类小泛素化。 T-RI类小泛素化反过来调节TGF-β信号依赖的癌细胞侵袭。 我们建议在分子水平上进一步表征这些信号事件的机制,并利用这些知识来解决它们在癌细胞行为和癌症进展中的作用。 目标1将重点关注TGF-β如何激活PI 3 K-Akt-TOR通路,以及TGF-β信号传导的这一组成部分在细胞侵袭和癌症进展中的作用。 目的2研究TGF-β激活的ShcA-Erk MAP激酶信号通路在EMT、侵袭和肿瘤进展中的作用。 目的3提出更好地表征T <$RI的sumoylation,并了解其在TGF-β反应和癌症进展中的作用。 我们对该计划的热情不仅是由其固有的科学重要性驱动的,而且也是由其转化潜力驱动的。 公共卫生相关性:在大多数情况下,导致死亡的癌症进展并不是第一个肿瘤生长的结果,而是因为肿瘤开始侵入其他组织并扩散到全身,从而产生更多的肿瘤,这一过程称为转移。 癌症的侵袭和转移是由一种叫做TGF-β的蛋白质驱动的,这种蛋白质是由肿瘤细胞本身产生的,并指示它们经历导致侵袭和转移的变化。 最近,发现了由TGF-β激活的新的信号通路,并补充了先前研究的受到所有关注的信号通路。 拟议的研究旨在更好地了解这些额外途径的分子基础及其在癌细胞行为,癌症进展和转移中的作用。 这一知识很可能提供新的和更有选择性的途径,比迄今为止可能阻止癌症的侵袭和转移行为。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

RIK M DERYNCK其他文献

RIK M DERYNCK的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('RIK M DERYNCK', 18)}}的其他基金

Central role of ShcA in differential TGF-beta signaling, epithelial plasticity and carcinoma cell behavior
ShcA 在差异 TGF-β 信号传导、上皮可塑性和癌细胞行为中的核心作用
  • 批准号:
    9105649
  • 财政年份:
    2016
  • 资助金额:
    $ 31.1万
  • 项目类别:
Central role of ShcA in differential TGF-beta signaling, epithelial plasticity and carcinoma cell behavior
ShcA 在差异 TGF-β 信号传导、上皮可塑性和癌细胞行为中的核心作用
  • 批准号:
    9894637
  • 财政年份:
    2016
  • 资助金额:
    $ 31.1万
  • 项目类别:
Central role of ShcA in differential TGF-beta signaling, epithelial plasticity and carcinoma cell behavior
ShcA 在差异 TGF-β 信号传导、上皮可塑性和癌细胞行为中的核心作用
  • 批准号:
    9452037
  • 财政年份:
    2016
  • 资助金额:
    $ 31.1万
  • 项目类别:
Central role of ShcA in differential TGF-beta signaling, epithelial plasticity and carcinoma cell behavior
ShcA 在差异 TGF-β 信号传导、上皮可塑性和癌细胞行为中的核心作用
  • 批准号:
    9237246
  • 财政年份:
    2016
  • 资助金额:
    $ 31.1万
  • 项目类别:
PRMT1 MEDIATED ARG METHYLATION OF INHIBITORY SMADS IN TGF-BETA SIGNALLING
PRMT1 介导 TGF-β 信号传导中抑制性 SMAD 的 ARG 甲基化
  • 批准号:
    8363822
  • 财政年份:
    2011
  • 资助金额:
    $ 31.1万
  • 项目类别:
PRMT1 MEDIATED ARG METHYLATION OF INHIBITORY SMADS IN TGF-BETA SIGNALLING
PRMT1 介导 TGF-β 信号传导中抑制性 SMAD 的 ARG 甲基化
  • 批准号:
    8169818
  • 财政年份:
    2010
  • 资助金额:
    $ 31.1万
  • 项目类别:
Regulatory non-Smad signaling in TGF-b-induced epithelial-mesenchymal transition
TGF-b 诱导的上皮间质转化中的调节性非 Smad 信号传导
  • 批准号:
    9197271
  • 财政年份:
    2009
  • 资助金额:
    $ 31.1万
  • 项目类别:
TGF-beta-induced non-Smad signaling events and cancer cell behavior
TGF-β诱导的非Smad信号传导事件和癌细胞行为
  • 批准号:
    7565384
  • 财政年份:
    2009
  • 资助金额:
    $ 31.1万
  • 项目类别:
TGF-b family signaling in cardiomyocyte differentiation from embryonic stem cells
胚胎干细胞向心肌细胞分化中的 TGF-b 家族信号传导
  • 批准号:
    7738990
  • 财政年份:
    2009
  • 资助金额:
    $ 31.1万
  • 项目类别:
Non-Smad Mechanisms of TGFBeta Signaling
TGFBeta 信号转导的非 Smad 机制
  • 批准号:
    7827981
  • 财政年份:
    2009
  • 资助金额:
    $ 31.1万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 31.1万
  • 项目类别:
    Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 31.1万
  • 项目类别:
    Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 31.1万
  • 项目类别:
    Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 31.1万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 31.1万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 31.1万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 31.1万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 31.1万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 31.1万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 31.1万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了